Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467896 · ClinicalTrials.gov registry record · Phase 2
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
A Phase 2 study, sponsored by Actelion.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00467896: Clinical Trial Phase 2 study, sponsored by Actelion.
NCT00467896 is a Phase 2 study that was terminated before completion, run by Actelion. The registered enrollment target is 62 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00467896, a Phase 2 study, was terminated before completion, sponsored by Actelion.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"
Primary Outcome
Defined as the percentage of full doses (5 µg) of iloprost delivered within the recommended time frame for receiving a full dose of iloprost (4-10 minutes). Iloprost dosing information was available from the I-neb® device, which recorded the date and time of each inhalation, the duration of each inhalation, as well as the inhalation completion status (\< 12.5%, ≥ 12.5% to \< 100%, and Full)
Interventions
- DRUG Iloprost PD-6
- DRUG Iloprost PD-15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2006-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Why NCT00467896 stopped before completion
NCT00467896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Iloprost PD-6 is the first listed.
NCT00467896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00467896 about?
NCT00467896 is a clinical study titled "The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting". A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"
What is the current status of trial NCT00467896?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2006-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00467896?
The interventions under investigation include: Iloprost PD-6 (DRUG), Iloprost PD-15 (DRUG).
Who is sponsoring clinical trial NCT00467896?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00467896's enrollment target sits among peer trials
62 1016th of 2000 higher than 975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia